Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Company

Novartis

Tracked across 16 events · 121 articles · First seen Apr 22, 2025 · Last active Jul 06, 2026

Sentiment
23
Attention
7
Events
16
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 20
Business
Impact: Novartis announced the expansion of its community health programs to address gaps in heart disease and cancer care globally, which could positively impact its public image and long-term market position.
Apr 09, 2026 · 7 articles
6 75
Regulatory
Impact: Novartis received International — European Commission approval for its gene therapy Itvisma, expanding its market reach for spinal muscular atrophy treatments and reinforcing its position in gene therapy. This approval is a significant positive for the company.
Jul 02, 2026 · 7 articles
6 70
Business
Impact: Novartis is acquiring Myricx Bio to strengthen its oncology pipeline with next-generation antibody-drug conjugates (ADCs) and novel NMTi payload mechanisms, expanding its options for cancer patients and potentially establishing a new class of ADC payloads.
Jul 05, 2026 · 21 articles
4 10
Business
Impact: Novartis settled a lawsuit with the estate of Henrietta Lacks over the unauthorized use of her cells, which were used to develop various medical advancements. This settlement resolves a significant legal and ethical challenge for Novartis.
Feb 26, 2026 · 7 articles
4 60
Business
Impact: Novartis, an innovative medicines company, is collaborating with the United Arab Emirates — Department of Health – Abu Dhabi to expand its global scientific expertise in genomics research and advanced therapies, potentially leading to new treatment developments and market opportunities.
Jun 26, 2026 · 6 articles
6 20
Regulatory
Impact: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
4 60
Tech
Impact: Novartis, the manufacturer of Onasemnogene abeparvovec, views this approval as a milestone in patient care and a reflection of its commitment to neurology and expanding its focus into neuroimmunology, neurodegenerative disorders, and neuromuscular diseases.
Dec 20, 2025 · 6 articles
6 60
Tech
Impact: Novartis is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments, showcasing the industry's move towards Pharma 4.0.
Apr 07, 2026 · 8 articles
7 -10
International
Impact: Novartis employed Jason Thomas, a pharmaceutical researcher who was found dead after disappearing, adding a pharmaceutical link to the broader pattern of mysterious deaths.
Apr 11, 2026 · 6 articles
3 0
Tech
Impact: Novartis was an attendee at the summit, suggesting its engagement with digital health technologies for clinical trials.
Jul 03, 2026 · 8 articles
2 0
Business
Impact: Novartis led AstronauTx's £48 million/$61 million Series A financing in October 2023.
May 12, 2026 · 6 articles
6 0
Business
Feb 04, 2026 · 6 articles
2 0
Business
Apr 09, 2026 · 7 articles
4 0
Business
May 12, 2026 · 6 articles
4 0
Business
Apr 27, 2026 · 7 articles
2 0
Business
Apr 24, 2026 · 6 articles
Roche Novartis
Roche Novartis
Switzerland Novartis
Switzerland Novartis
ERGEN INTELLIGENCE
Track Novartis live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.